The Gamaleya Institute Covid-19 Vaccine as Drug Nears Approval

A lab technician works at a microscope during production of the 'Medgamal' COVID-19 vaccine, developed by the Gamaleya National Research Center for Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF), at the Gamaleya National Research Center in Moscow, Russia, on Thursday, Aug. 6, 2020. Some medical staff and city government workers in Moscow are being offered the opportunity to inoculate against the coronavirus as Russia is poised to register what it says is the worlds first Covid-19 vaccine. Photographer: Andrey Rudakov/Bloomberg via Getty Images
A lab technician works at a microscope during production of the 'Medgamal' COVID-19 vaccine, developed by the Gamaleya National Research Center for Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF), at the Gamaleya National Research Center in Moscow, Russia, on Thursday, Aug. 6, 2020. Some medical staff and city government workers in Moscow are being offered the opportunity to inoculate against the coronavirus as Russia is poised to register what it says is the worlds first Covid-19 vaccine. Photographer: Andrey Rudakov/Bloomberg via Getty Images
The Gamaleya Institute Covid-19 Vaccine as Drug Nears Approval
PURCHASE A LICENCE
How can I use this image?
£375.00
GBP

DETAILS

Restrictions:
Contact your local office for all commercial or promotional uses.For editorial use only. Additional clearance required for commercial or promotional use, contact your local office for assistance. Any commercial or promotional use of Bloomberg content requires Bloomberg's prior written consent.
Credit:
Bloomberg / Contributor
Editorial #:
1227946057
Collection:
Bloomberg
Date created:
06 August, 2020
Upload date:
Licence type:
Rights-managed
Release info:
Not released. More information
Source:
Bloomberg
Object name:
RUSSIA VACCINE
Max file size:
4000 x 2667 px (33.87 x 22.58 cm) - 300 dpi - 3 MB